These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Rare Mutations in Cancer Drug Resistance and Implications for Therapy. Beckman RA; Loeb LA Clin Pharmacol Ther; 2020 Sep; 108(3):437-439. PubMed ID: 32648584 [No Abstract] [Full Text] [Related]
6. Associating somatic mutations to clinical outcomes: a pan-cancer study of survival time. Little P; Lin DY; Sun W Genome Med; 2019 May; 11(1):37. PubMed ID: 31138328 [TBL] [Abstract][Full Text] [Related]
7. Blood Worth Bottling: Circulating Tumor DNA as a Cancer Biomarker. Christie EL; Dawson SJ; Bowtell DD Cancer Res; 2016 Oct; 76(19):5590-5591. PubMed ID: 27698187 [No Abstract] [Full Text] [Related]
9. Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Yuan Y; Van Allen EM; Omberg L; Wagle N; Amin-Mansour A; Sokolov A; Byers LA; Xu Y; Hess KR; Diao L; Han L; Huang X; Lawrence MS; Weinstein JN; Stuart JM; Mills GB; Garraway LA; Margolin AA; Getz G; Liang H Nat Biotechnol; 2014 Jul; 32(7):644-52. PubMed ID: 24952901 [TBL] [Abstract][Full Text] [Related]
10. Complexities of Variant Classification in Clinical Hereditary Cancer Genetic Testing. Mundt E; Nix P; Brown K; Bowles KR; Manley S J Clin Oncol; 2017 Dec; 35(34):3796-3799. PubMed ID: 28981386 [No Abstract] [Full Text] [Related]
11. Tumor Heterogeneity in Breast Cancer. Badve S; Gökmen-Polar Y Adv Anat Pathol; 2015 Sep; 22(5):294-302. PubMed ID: 26262511 [TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of malignant tumors should be considered when performing flow cytometric DNA analysis. Zhang XH; Xie TX Cytometry; 1995 Jun; 22(2):158-9. PubMed ID: 7587750 [No Abstract] [Full Text] [Related]
13. Melanoma with BRAF Mutation in Circulating Cell-free DNA despite no Mutation in the Primary Lesion: A Case Report. Ashida A; Uhara H; Mikoshiba A; Sakaizawa K; Kumagai N; Koga H; Okuyama R Acta Derm Venereol; 2016 Jan; 96(1):128-9. PubMed ID: 26123241 [No Abstract] [Full Text] [Related]
14. Molecular pathology in real time. Ryška A Cancer Metastasis Rev; 2016 Mar; 35(1):129-40. PubMed ID: 26931654 [TBL] [Abstract][Full Text] [Related]
15. Foreword. Croce CM Adv Exp Med Biol; 2015; 889():v. PubMed ID: 26933700 [No Abstract] [Full Text] [Related]
17. A population genetics perspective on the determinants of intra-tumor heterogeneity. Hu Z; Sun R; Curtis C Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):109-126. PubMed ID: 28274726 [TBL] [Abstract][Full Text] [Related]
18. Towards Clinical Application of Methylated DNA Sequences as Cancer Biomarkers: A Joint NCI's EDRN and NIST Workshop on Standards, Methods, Assays, Reagents and Tools. Kagan J; Srivastava S; Barker PE; Belinsky SA; Cairns P Cancer Res; 2007 May; 67(10):4545-9. PubMed ID: 17510378 [TBL] [Abstract][Full Text] [Related]
19. The UCSC Cancer Genomics Browser. Zhu J; Sanborn JZ; Benz S; Szeto C; Hsu F; Kuhn RM; Karolchik D; Archie J; Lenburg ME; Esserman LJ; Kent WJ; Haussler D; Wang T Nat Methods; 2009 Apr; 6(4):239-40. PubMed ID: 19333237 [No Abstract] [Full Text] [Related]
20. [Clinical significance of carriage of rare variants of connexin-26 genetic polymorphism in gastric cancer]. Sedov VM; Iaitskiĭ AN; Mozgovoĭ ED; Volkov NM; Moiseenko FV; Dubina MV; Krutovskikh VA Vestn Khir Im I I Grek; 2007; 166(6):11-4. PubMed ID: 18411733 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]